Last year was a tough one for IPOs, as Matt noted earlier, and so far this year looks even worse. Aptamer-drug maker Archemix today became the third life-science startup this month to withdraw or postpone an IPO, and the sixth so far this year. We take a closer look at the worsening IPO climate and the contrast with still-bullish venture funding in the sector, over at VentureBeat Life Sciences.
Top Stories
- Spotted: FriendFeed Beta -- coming soon
- iPhone app developers report to OpenClip.org immediately. ...
- Fanboys unite: Google and Apple trounce rivals ...
- A first look at the Google Android ...
- ComScore: Travel, retail and celebrity news sites ...
Featured Guest Columnists
- David Gal
Is Facebookâs Platform a strategic mistake? - Richard Wong
View from Barcelona: The end of the operator-dominated era? - Bernard Moon
U.S. tech trends for 2008
Job Board
- Director, Business Development
at MySpace (San Francisco, CA, USA) - Sr. SW Engineer - Eclipse Plug-in/RCP
at Silver Key, Inc. (Mountain View, CA) - Alliance Marketing
at Sun Microsystems (MENLO PARK, CA) - More Jobs » | Post a Job »
Links
Venturebeat Writers
- Matt Marshall, Editor-in-Chief
- Dean Takahashi, Lead Writer, DigitalMedia
- Eric Eldon, Editor, DigitalMedia
- David Hamilton, Editor, LifeScience
- MG Siegler, Writer, DigitalMedia
- Anthony Ha, Writer, VentureBeat
- Chris Morrison, Writer, CleanTech
- For advertising, contact .
- Log in
Font Size
© 2004-2008(c) Matt Marshall. All rights reserved.Site produced by RubyRed Labs, Evan Levelle
powered by Wordpress
11:14 am
Life sciences briefing: Monday, Feb. 18, 2008 » VentureBeat said:
[...] infusion services, dropped its proposed $125 million IPO. The withdrawal isn’t related to the broader slump in health-related IPOs, which has claimed eight proposed offerings so far this year, as Critical Healthcare agreed last [...]